13F filer · CIK 2010850
Decheng Capital LLC
MENLO PARK, CA · filing since Q4 2023 · last filing Aug 14, 2026
Reported value
$731.7M
+$70.4M vs prior
Positions
14
New / sold out
1 / 1
Added / reduced
0 / 3
Turnover
0.1%
buys $625.2K · sells $15.0M
Top-10 weight
98.1%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | TANGO THERAPEUTICS INC | +20,000 | – | +$625.2K |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | REVOLUTION MEDICINES INC(NSM) | -40,833 | -43.7% | $-7.6M |
| Reduced | NEWAMSTERDAM PHARMA CO NV | -148,170 | -45.6% | $-5.0M |
| Sold out | KRYSTAL BIOTECH INC | -7,300 | -100.0% | $-1.9M |
| Reduced | Arcus Biosciences, Inc | -13,040 | -2.7% | $-402.0K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | CG ONCOLOGY INCCOM | 6,371,669 | $452.7M | 61.87% |
| 2 | Nuvation Bio Inc.COM | 25,954,439 | $147.4M | 20.15% |
| 3 | AARDVARK THERAPEUTICS INCCOM | 3,917,299 | $22.6M | 3.08% |
| 4 | Aclaris Therapeutics, Inc.COM | 4,041,736 | $21.4M | 2.92% |
| 5 | Upstream Bio Inc.COM | 2,724,868 | $18.9M | 2.58% |
| 6 | Arcus Biosciences, IncCOM | 464,779 | $14.3M | 1.96% |
| 7 | Equillium Inc.COM | 4,447,308 | $14.2M | 1.94% |
| 8 | REVOLUTION MEDICINES INC(NSM)COM | 52,667 | $9.9M | 1.35% |
| 9 | Lyell Immunopharma, Inc.COM | 692,050 | $9.7M | 1.33% |
| 10 | BeyondSpring Inc.SHS | 3,800,702 | $6.7M | 0.91% |
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.